Piper Sandler Reiterates Overweight Rating on BioCryst Pharma (BCRX)

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/18/2026

1. VRNS
2. JBHT
3. CRWV
4. TSLA
5. SCHW
6. GPRK
7. TRV
8. TFC
9. USB
10. SPY

Go back to Piper Sandler Reiterates Overweight Rating on BioCryst Pharma (BCRX)

JPMorgan Reiterates Overweight Rating on BioCryst Pharma (BCRX)

February 24, 2025 8:58 AM EST

JPMorgan analyst Jessica Fye reiterated an Overweight rating and $10.00 price target on BioCryst Pharma (NASDAQ: BCRX)

The analyst comments "We think the ~3% upward guidance revision to FY25 Orladeyo revs by ~$18mm at the midpoint to $535-$550mm (vs prior guidance of $515-$535mm established earlier this year at our healthcare conference) will be well received as it supports 24% growth YoY for Orladeyo at the midpoint after 34% Orladeyo growth in 24. Well listen... More

BioCryst Pharma (BCRX) Misses Q4 EPS by 6c; offers outlook

February 24, 2025 7:29 AM EST

BioCryst Pharma (NASDAQ: BCRX) reported Q4 EPS of ($0.13), $0.06 worse than the analyst estimate of ($0.07). Revenue for the quarter came in at $131.53 million versus the consensus estimate of $127.17 million.

OUTLOOK

Financial Outlook for 2025

Based on the early... More